Category: Public Policy

Proposed Changes for Protected Class Drugs for Medicare Part D

Thanks to those who adovcate on behalf of the Tourette Syndrome community, the proposed changes to Protected Class Drugs for Medicare Part D were not included.
Read more

The Importance of Educating Your Congressional Representatives

The importance of contacting your Representatives and Senators about Tourette Syndrome related issues and programming at their local offices.
Read more

A Thank You to Chapter and Support Group Leaders

A special thank you to the chapter and support group leaders that helped with outreach to members of congress.
Read more

The Impact of Advocacy Day 2019

Read a general summary on Advocacy Day and its impact on Tourette Syndrome.
Read more

Protected Class Drugs in Medicare Part D

The Tourette Association of America has submitted comments on the proposed changes to protected class drugs in Medicare Part D.
Read more

The Importance of Telehealth for the TS Community

For patients with Tourette Syndrome (TS) and Tic Disorders, it can be difficult to find specialists and many drive hours or travel lengthy distances for physician visits. This is especially true in rural areas.  The ability to conduct medical appointments/evaluations through a computer or electronic platform via telehealth could reduce leave from work and travel costs.
Read more

Public Policy Update

The President recently signed into law the Defense, Labor-HHS-Education Appropriations for Fiscal Year (FY) 2019 which included the continued funding of $2 million for the Centers for Disease Control and Prevention (CDC) Tourette Syndrome Public Health Education and Research Program. This program is critical for the Tourette Syndrome (TS) and Tic Disorder community.
Read more

Ensuring Access to Treatment – Drug Pricing

You likely have heard about the President’s Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs in the news.  The President requested comments on a broad range of potential changes to increase competition and reduce drug prices.  One thing is clear, how drug prices are created is not simple or very transparent and will depend on many factors, including your prescription benefit manager (PBM).  This complex system has been built over time and many parts of the system are interwoven and impact each other directly or indirectly.  As such, it is extremely important that any actions taken to improve the system are fully understood and that all impacts, direct and indirect, are fully assessed before enacting change.  TAA submitted comments to the Administration requesting that patient needs should be a top priority and have requested that any further action follows the official rule-making process which would allow further comments during the process.  TAA will continue to work with the National Health Council and other like-minded patient groups to ensure our voices are heard as the process moves forward.   TAA Comments HHS Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs   Meeting your Representative and
Read more